Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?

Clin Investig Arterioscler. 2020 Jan-Feb;32(1):30-32. doi: 10.1016/j.arteri.2019.04.003. Epub 2019 Jun 17.
[Article in English, Spanish]

Abstract

Inhibitors of the protein PCSK9, available since 2015, are capable of reducing the concentration of low density lipoprotein cholesterol by 40 to 70%, thus reducing the cardiovascular risk. The present case reports an adverse cardiovascular event that appeared when spacing out the administration of lipid-lowering treatment. A discussion will be presented on the importance of maintaining low cholesterol levels in order to achieve a greater benefit, according to the latest published clinical studies.

Keywords: Alirocumab; Cardiovascular events; Evento cardiovascular; Inhibidores de PSCK9; c-LDL; iPCSK9 inhibitors.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / adverse effects
  • Cholesterol, LDL / blood
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Hypercholesterolemia / drug therapy
  • Ischemic Attack, Transient / chemically induced*
  • Male
  • PCSK9 Inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • alirocumab